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Background: Early diagnosis of initial metabolic derangements in young obese children could influence their
management; however, this impairment is frequently not overt, but subtle and undetectable by routinely used
clinical assays. Our aim was to evaluate the ability of serum proteomic analysis to detect these incipient metabolic
alterations in comparison to standard clinical methods and to identify new candidate biomarkers.
Methods: A cross-sectional study of fasting serum samples from twenty-two prepubertal, Caucasian obese (OB;
9.22 ± 1.93 years; 3.43 ± 1.08 BMI-SDS) and twenty-one lean controls (C; 8.50 ± 1.98 years; -0.48 ± 0.81 BMI-SDS) and a
prospective study of fasting serum samples from twenty prepubertal, Caucasian obese children (11 insulin resistant
[IR]) before (4.77 ± 1.30 BMI-SDS) and after weight reduction (2.57 ± 1.29 BMI-SDS) by conservative treatment in a
reference hospital (Pros-OB) was performed. Proteomic analysis (two-dimension-eletrophoresis + mass spectrometry
analysis) of serum and comparative evaluation of the sensitivity of routinely used assays in the clinics to detect the
observed differences in protein expression level, as well as their relationship with anthropometric features, insulin
resistance indexes, lipid profile and adipokine levels were carried out.
Results: Study of the intensity data from proteomic analysis showed a decrease of several isoforms of
apolipoprotein-A1, apo-J/clusterin, vitamin D binding protein, transthyretin in OB vs. C, with some changes in these
proteins being enhanced by IR and partially reversed after weight loss. Expression of low molecular weight isoforms
of haptoglobin was increased in OB, enhanced in IR and again decreased after weight loss, being positively
correlated with serum interleukin-6 and NAMPT/visfatin levels. After statistical correction for multiple comparisons,
significance remained for a single isoform of low MW haptoglobin (OB vs. C and IR vs. non-IR) and Apo A1 (IR vs.
non-IR). Assays routinely used in the clinical setting (ELISA/kinetic nephelometry), only partially confirmed the
changes observed by proteomic analysis (ApoA1 and haptoglobin).
Conclusion: Proteomic analysis can allow for the identification of potential new candidate biomarkers as a
complement to routinely used assays to detect initial changes in serum markers of inflammation and lipid
metabolism impairment in young obese children.
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Early-onset obesity is a definite risk factor for adult obesity,
its associated comorbidities and reduced life expectancy
[1,2]. Most of the metabolic comorbidities overtly observed
in obese adults are usually subtle or even undetectable
in most young (prepubertal) obese children when the cur-
rently available biomarkers, including the growing number
of adipokines, are used. Adipokines play a preeminent role
in carbohydrate metabolism, the derangement of which
is the most important metabolic comorbidity of obesity,
which can ultimately lead to type 2 diabetes mellitus
([T2DM] [3,4]). Impaired adipokine synthesis and secre-
tion, which can be detected even in young obese children,
contributes to the generation of insulin resistance (IR) in a
dual fashion. Obesity induces changes in serum levels of
insulin sensitizing adipokines [4-7] and also generates a
generalized proinflammatory environment by increasing
the circulating levels of resistin, interleukin 6 (IL-6) and tu-
moral necrosis factor alpha (TNF-α) [6,8]. However, these
changes in circulating adipokines related with carbohydrate
metabolism have not been shown to be of value for the de-
tection of early stages of homeostatic derangement in
young obese children. Hence, there is a lack of sensitive
markers for the initial stages of carbohydrate metabolism
impairment in childhood obesity. A similar situation is ob-
served with regard to the obesity related impairment of
lipid metabolism, mainly represented by the decrease in
high density lipoprotein (HDL) levels in this age range and
definitely influenced by the existence of IR.
Consequently, analysis of the serum proteome of young
children in different weight-related conditions (normal,
excess and later reduction), with or without IR, could be
useful for the detection of new more sensitive diagnostic
biomarkers. An advantageous tool for the study of the cir-
culating proteome in serum under different conditions is
the use of two dimension electrophoresis (2DE). This
technique allows for the isolation and identification of
proteins in a given sample and has previously been applied
to human serum samples for different purposes, with a
limited amount (below 0.5 ml) of serum needed to identify
up to 300 protein spots [9-12]. Therefore, the aims of this
study were: 1) To investigate the influence of obesity and
weight loss on the serum proteomic profile of young pre-
pubertal obese children. 2) To evaluate the differences in
the serum proteome between young obese children ac-
cording to the presence or lack of estimated IR and 3) To
identify new candidate biomarkers of early metabolic im-
pairment in young obese children.
Subjects and methods
Subjects
Three groups of children were enrolled for this study:
obese patients (OB), controls (C) and a second cohort of
prospectively followed obese patients (Pros-OB).Obese patients (OB)
This group was made up of twenty-two prepubertal
(Tanner stage I) obese (BMI > +2 SDS according to
Spanish standards [13]) Caucasian children (13 males / 9
females). Their mean age at recruitment was 9.22 ± 1.93
years (range 5.53-12.89) and their mean BMI 3.43 ± 1.08
SDS. Samples from these patients were obtained exclu-
sively at the time of enrollment in the study.
Control group (C)
This group was made up of twenty-one prepubertal
(Tanner stage I) lean (BMI between -1.5 and + 1.5 SDS
according to Spanish standards [13]) Caucasian children
(16 boys/ 4 girls). Their mean age at recruitment was
8.50 ± 1.98 years (range 5.64-11.95) and their mean
BMI -0.48 ± 0.81 SDS. These children were referred to
our department but found to be healthy, with no patho-
logical auxological, clinical or analytical findings. Sam-
ples from controls were obtained exclusively at the time
of enrollment in the study.
Prospectively followed obese patients (Pros-OB)
A subgroup of a larger cohort of obese patients that
were prospectively followed for 18 months in an inten-
sive program of behavioural modification [6] was used
in these studies. It was made up of twenty children, all
of whom had achieved extensive BMI reduction (over 2
SDS regarding their BMI at enrollment) during the first
12 months of follow-up. All of them were prepubertal
(Tanner stage I), obese (BMI > +2 SDS according to
Spanish [13]) and Caucasian (16 boys/ 4 girls). Their
mean age at recruitment was 8.64 ± 1.56 years (range
5.44-11.70) and serum samples were obtained at two dif-
ferent time-points: at diagnosis (D, mean BMI 4.77 ±
1.30 SDS) and after reducing their BMI by over 2 SDS
(weight loss [WL], mean BMI 2.57 ± 1.29 SDS). These
patients underwent an oral glucose tolerance test at D
(OGTT, 1.75g/kg, maximum 75g) to estimate their de-
gree of IR. Body composition analyses were performed
by DXA (Hologic QDR4500W) at time-points D and
WL, confirming that the observed weight loss was due
exclusively to body fat mass reduction, without bone
density or lean mass impairment [6]. Blood samples
were obtained at both time-points (D and WL).
All samples were obtained after overnight fasting.
Those samples from children in groups OB and C were
centrifuged and serum stored at –80°C until preparation
for proteomic analysis. The samples from the patients in
the Pros-OB, both at D and at WL, underwent a lyophy-
lization process for better preservation after collection
and were reconstituted immediately before preparation
for proteomic analysis.
All patients and controls and their parents or guard-
ians gave informed consent as required by the local
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study. The study was also approved by the Ohio Univer-
sity Institutional Review Board.
Biochemical measurements
Serum lipid profile (triglycerides, total cholesterol, HDL,
LDL and VLDL), glucose, insulin, total (T) and high mo-
lecular weight (HMW) adiponectin, resistin, IL-6, TNF-
α, NAMPT/visfatin and vaspin levels were measured in
separated aliquots of each sample by using commercial
assays as previously reported [6,7]. The findings in prote-
omic analysis were contrasted with validated commercial
assays by ELISA [Apolipoprotein-A1 (Apo-A1; Assaypro(R)),
haptoglobin (Assaypro(R)), apo-J/clusterin (BioVendor(R)),
alpha-1B-acid glycoprotein (α-1-BAGP; Assaypro(R)), alpha-
1-antitrypsin (α1-AT; Assaypro(R)); vitamin D binding pro-
tein (vD-BP; R&D Systems(R)); retinol binding protein 4
(RBP4; R&D Systems(R))] or kinetic nephelometry [trans-
thyretin (Immage. Beckman(R)].
HOMA index was calculated as glucose [mmol/l] ×
insulin [μUI/ml]/22.5 and SA as HMW-(μg/ml)/(T)-adipo-
nectin(μg/ml). IR was estimated in patients in the Pros-
OB at D according to the patient’s insulin secretion rate
in the OGTT and classified at baseline as insulin resistant
(IR, n = 11) if they met any of the following criteria: basal
insulin > 15 μU/ml, peak insulin > 150 μU/ml or insulin at
120 minutes > 75 μU/ml or as not IR (non-IR, n = 9) if
they did not [14].
Sample preparation for proteomic analysis
The serum samples were thawed or reconstituted (accord-
ing to their preservation process). Fifty milliliters of each
selected serum sample were albumin and Ig-G-depleted
using an albumin and IgG Depletion kit (ProteoPrep® Blue
Albumin Depletion Kit, Sigma-Aldrich, St. Louis, MO) and
diluted in sample buffer containing 7 M urea, 2 M thio-
urea, 1% w/v SB 3–10, 3% w/v CHAPS, 0.25% v/v Bio-Lyte
3/10 ampholytes (Bio-Rad Laboratories Inc., Hercules,
CA), and 1.5% v/v protease inhibitor cocktail (Sigma, St.
Louis, MO). Disulfide bonds were reduced by addition of
tributylphosphine and sulfhydryl groups were alkylated
with iodoacetamide.
Two-dimensional gel electrophoresis (2DE) + mass
spectrometry (MS)
All of the 2DE, image processing and analysis, mass
spectrometry (MS) and tandem MS (MS-MS) analysis
procedures (MALDI-TOF) have been detailed previ-
ously for human samples [9-12,15]. Identities obtained
after MS and MS-MS analysis were verified using the MS
and MS/MS data obtained to search online databases
with the software Mascot (www.matrixscience.com)
[9-12,15].Sets of comparison
Due to the different sample processing and preservation
procedures undergone by the samples from the patients
in the Pros-OB group (lyophylization), regarding the OB
and C groups (exclusively freezing), the obese patients
from these groups were not pooled for analysis at base-
line. The following sets of comparison were established
in order to achieve the proposed objectives avoiding any
possible bias derived from differences in the process of
sample preservation:
1) Influence of obesity on serum proteomic profile: OB
(n = 22) vs. C (n = 21).
2) Differences in the serum proteome due to insulin
resistance: Pros-OB group at baseline (B): IR (n = 11)
vs. non-IR (n = 9).
3) Effect of extensive weight reduction on serum
proteomic profile: Pros-OB: Paired comparison
between time-points D and WL (n = 20 at each
time-point).
Statistical analysis
All 2DE intensity data were log-transformed. Variables
fitting a normal distribution (p > 0.05 in a Shapiro–Wilk
test) were compared between pairs of groups using a
Student-t test for independent samples (OB vs. C; IR vs.
non-IR) or a paired t-test for repeated samples (D vs.
WL). The remaining variables were analyzed using the
nonparametric Mann & Whitney U test (OB vs. C; IR vs.
non-IR) or Wilcoxon test (D vs. WL). Correlation ana-
lysis was performed by using Pearson’s r or Spearman’s
rho for parametric and non parametric variables, re-
spectively. A value of p < 0.05 was chosen as the level of
significance. These tests were performed using the soft-
ware Statistical Package for Social Sciences (SPSS v.
14.0. MapInfo Corporation, Troy, NY, USA). Due to the
high number of variables considered for every compari-
son set, statistical correction for multiple comparisons
was performed by using the false discovery rate (FDR)
test after initial comparisons (PRISM v. 6.0. GraphPad
Software, Inc., La Jolla, CA, USA).
Results
Influence of obesity on the serum proteomic profile
The study of the serum proteomic profile in OB (n = 22)
and C (n = 21) allowed for the analysis of 231 protein
spots. The comparison of the protein spot intensities re-
vealed that 17 of them showed differences between
groups (p < 0.05). Among these, 6 proteins were over-
expressed in OB compared to C, whereas the expression
of the remaining 11 protein spots was decreased in OB
(Table 1, Figure 1).
Among the observed changes, the down-regulation of
several isoforms of Apo A1 (#2201, #3201, #3202; #6203;
Table 1 Protein spot displaying intensity differences (p < 0.05) between obese children (OB) and controls (C) before
FDR analysis
Spot














1809 Upregulated, p < 0.05 68/66 15 26 45/40 2 (1) 6 Alpha 1B acid glycoprotein
2201 Downregulated, p < 0.01 115/66 12 50 98/41 9 (6) 40 Apolipoprotein A1
2203 Downregulated, p < 0.05 44/66 3 – 102/41 3(3) 6 Clusterin (Apolipoprotein J)
2301 Downregulated, p < 0.05 56/66 7 – 95/41 5(4) 23 Clusterin (Apolipoprotein J)
2306 Upregulated, p < 0.05 75/66 7 30 71/41 6(2) 17 Haptoglobin
3201 Downregulated, p < 0.05 137/66 16 59 81/41 8(4) 33 Apolipoprotein A1
3202 Downregulated, p < 0.01 71/66 8 34 81/41 6(4) 25 Apolipoprotein A1
3307 Upregulated, p < 0.05 91/66 7 36 61/58 3(1) 6 Haptoglobin
4401 Downregulated, p < 0.05 68/66 6 83 95/59 2(2) 28 Transthyretin chain A
5603 Downregulated, p < 0.05 71/66 6 11 79/59 3(1) 6 Haptoglobin
5604 Downregulated, p < 0.01 82/66 11 49 84/58 2(1) 4 Haptoglobin
6203 Downregulated, p < 0.05 127/66 17 65 76/58 6(3) 29 Apolipoprotein A1
7102 Upregulated, p < 0.01 55/66 8 – 64/56 2(1) 13 Haptoglobin (alpha2)
7201 Downregulated, p < 0.01 106/66 16 66 76/59 3(2) 13 Apolipoprotein A1
7503 Downregulated, p < 0.05 53/66 5 – 64/58 2(2) 7 Vitamin D binding protein
8102 Upregulated, p < 0.01 68/66 5 20 70/57 3(1) 8 Haptoglobin (alpha2)
9101 Upregulated, p < 0.05 49/66 3 – 105/55 1(1) 4 Haptoglobin (alpha2)
Protein spots displaying significant intensity differences between obese children (OB) and controls (C) prior to the false discovery rate (FDR) analysis. The spot in
bold (8102) remained significantly different after FDR analysis. The second column shows the direction of the change observed in OB vs. C. Abbreviations: MS Mass
spectrometry; MS-MS Tandem mass spectrometry.
Figure 1 Proteomic profile comparison of OB vs. C. Protein identification of spots displaying differences (p < 0.05) between obese (OB) and
control (C) children before FDR analysis. For spot identification, please see Table 1.
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Table 2 Correlation between BMI-SDS and protein spot
intensity
Protein Correlation Protein Correlation
#2201 (ApoA1) r = -0.41;
p < 0.01
#5604 (Haptoglobin) r = -0.42;
p < 0.05
#2203 (Clusterin) r = -0.38;
p < 0.05
#6203 (ApoA1) r = -0.36;
p < 0.05
#2301 (Clusterin) r = -0.32;
p < 0.05
#7102 (HP) r = +0.36;
p < 0.05
#3201 (ApoA1) r = -0.32;
p < 0.05
#7201 (ApoA1) r = -0.35;
p < 0.05
#3202 (ApoA1) r = -0.43;
p < 0.05
#8102 (HP) r = +0.44;
p < 0.01
#3307 (HP) r = +0.32;
p < 0.05
#9101 (HP) r = +0.44;
p < 0.01
#5603 (HP) r = -0.35;
p < 0.05
Correlation coefficients (Spearman’s rho) and significance levels between
patient’s standardized BMI (SDS) and protein spot intensity in the whole
cohort of 43 prepubertal children studied, made up of 22 obese (OB) and 21
controls (C). Abreviations: ApoA1 Apoprotein A1, HP Haptoglobin.
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and transthyretin (#4401) was remarkable. OB patients
showed a decreased expression of the highest molecular
weight (MW) isoforms of haptoglobin (#5603, #5604),
whereas those isoforms with a medium (#2306; #3307)
or low MW (#7102; #8102; #9101) were up-regulated, as
was α-1-BAGP (#1809).
After FDR analysis, only differences between groups in
spot #8102 (low MW haptoglobin) remained significant
(p < 0.001).
When analyzed by ELISA, lower serum levels of Apo-A1
(120.7 ± 56.9 vs. 236.3 ± 91.7 mg/dl, p < 0.001) in OB were
observed, as was HDL cholesterol (46.22 ± 10.64 vs. 62.87 ±
12.53 mg/dl, p < 0.001). Similarly, ELISA was successful in
discriminating the increase in α-1-BAGP (179.3 ± 78.2 vs.
125.8 ± 49.1; p < 0.01) and total haptoglobin (162.5 ± 103.5
vs. 85.84 ± 60.63 mg/dl) in OB vs. C.
In contrast, ELISA assays did not detect differences
between OB and C in serum clusterin/Apo J (61.07 ±
9.75 vs. 57.29 ± 12.81 mcg/ml) or vD-BP levels (223.1 ±
62.5 vs. 236.2 ± 71.2 mcg/ml). No differences between
groups were found after transthyretin quantification by
kinetic nephelometry (22.72 ± 6.23 vs. 22.71 ± 4.91 mcg/
ml), nor in its substrate (RBP4) serum levels by ELISA
(750.3 ± 206.8 vs. 794.9 ± 173.2 mcg/ml).
To explore the eventual effect of excess BMI on the
expression of these protein spots, correlation studies
were performed in the whole study group (22 OB + 21
C: n = 43) between the relative intensity of spots showing
differences between groups prior to the FDR analysis
and the BMI-SDS of the patients. As expected, signifi-
cant negative correlations were found between BMI-SDS
and several isoforms of Apo-A1, clusterin/Apo J , vD-BP
and haptoglobin isoforms with high MW, whereas posi-
tive correlation coefficients were observed exclusively
with those haptoglobin isoforms with a lower MW, in-
cluding spot #8102 (Table 2).
Effect of insulin resistance on serum proteomic profile
Comparison of the serum proteomic profile between IR
(n = 11) and non-IR (n = 9) obese children (the Pros-OB
group at diagnosis) allowed for the analysis of 237 pro-
tein spots, with 12 of them showing differences between
groups (p < 0.05). Among these, 5 proteins were over-
expressed in IR compared to non-IR obese children,
whereas the expression of the remaining 7 protein spots
was decreased in IR (Table 3, Figure 2).
Among the observed changes, it was remarkable that
the presence of IR in obese children induced a further
down-regulation of isoforms of Apo-A1 (#3101; #4101;
#4103) and clusterin/Apo J (#3301; #4402). In contrast,
no significant differences between the IR and non-IR
groups were found in serum levels of clusterin/Apo J
(54.67 ± 14.70 vs. 56.87 ± 14.80 mg/dl), Apo-A1 (235.4 ±74.4 vs. 250.5 ± 79.4 mg/dl) or HDL (45.79 ± 8.82 vs.
45.89 ± 10.40 mg/dl) using standard immuno and en-
zymatic assays.
IR obese children also showed an increased expression of
the 4 low MW isoforms of haptoglobin (#3002; #7101;
#8101; #9101) and one of α1-AT (#1703), whereas the
haptoglobin isoforms with the highest MWs (#4503; #5503)
were down-regulated. When analyzed by ELISA, no signifi-
cant differences between the IR and non-IR groups were
found in serum levels of haptoglobin (202.7 ± 109.6 vs.
149.5 ± 49.5) or α1-AT (124.6 ± 60.1 vs. 115.2 ± 70.8).
After FDR analysis, differences between groups in
spots #4101 (Apo A1) and #8101 (low MW haptoglobin)
remained significant (both p < 0.0001).
To explore the relationship between the level of expres-
sion of these proteins and insulin resistance, the correlation
between the relative intensity of protein spots showing dif-
ferences between groups and the HOMA index of each pa-
tient in the entire study group was determined. As
expected, significant negative correlations were found be-
tween HOMA and several isoforms of Apo-A1 (including
spot #4101; rho -0.40 to -0.48; p < 0.05) and clusterin/Apo
J (rho -0.45; p < 0.05), whereas positive correlation coeffi-
cients were observed with low MW isoforms of haptoglo-
bin (including spot #8101; r = +0.55 to +0.61; p < 0.01).
Similar correlation studies were performed between
these protein spot intensities at diagnosis and circulating
levels of adipokines and the HMW to T adiponectin ra-
tio (SA index). No significant correlations were found for
HMW adiponectin, T- adiponectin or SA, or for resistin,
TNF-alpha or vaspin. In contrast, a significant positive
correlation was found between serum IL-6 levels and the
intensity of protein spots #8101 (r = +0.53; p < 0.05) and
Table 3 Protein spot displaying intensity differences (p < 0.05) between insulin resistant (IR) and non-IR obese children
before FDR analysis
Spot
Spot intensity in IR, MS MS MS MS -MS MS-MS MS-MS








1703 Upregulated, p < 0.05 111/66 15 54 100/40 6(4) 26 Alpha-1-Antitrypsin
3002 Upregulated, p < 0.05 48/66 4 – 52/38 1(1) 4 Haptoglobin
3101 Downregulated, p < 0.05 160/66 20 69 116/40 11(8) 43 Apolipoprotein A1
3301 Downregulated, p < 0.05 85/66 7 22 79/41 5(4) 23 Clusterin (Apo J)
4101 Downregulated, p < 0.01 165/66 23 73 150/49 11(5) 43 Apolipoprotein A1
4103 Downregulated, p < 0.05 161/66 22 73 171/59 11(4) 43 Apolipoprotein A1
4402 Downregulated, p < 0.05 49/66 5 – 97/58 1(1) 4 Clusterin (Apo J)
4503 Downregulated, p < 0.05 93/66 13 33 72/59 6(2) 15 Haptoglobin
5503 Downregulated, p < 0.05 56/66 6 – 81/59 2(0) 4 Haptoglobin
7101 Upregulated, p < 0.05 74/66 6 20 99/56 2(1) 7 Haptoglobin
8101 Upregulated, p < 0.05 55/66 5 – 73/56 2(1) 13 Haptoglobin
9101 Upregulated, p < 0.05 49/66 3 – 105/55 1(1) 4 Haptoglobin
The second column shows the direction of the change observed in IR vs. non-IR. Abbreviations: MS Mass spectrometry, MS-MS Tandem mass spectrometry.
Spots in bold remained significant after FDR analysis.
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MW isoforms of haptoglobin. Serum visfatin levels were
negatively correlated with the intensity of spot #3301
(clusterin/Apo J); r = -0.54; p < 0.05.
Effect of extensive weight reduction on the serum
proteomic profile
The paired comparison of the serum proteomic profiles of
20 obese children (the Pros-OB group), at diagnosis (D)
and after reducing their BMI in over 2 SDS (WL) (n = 20
at each time-point) allowed for the analysis of 237 proteinFigure 2 Proteomic profile comparison of IR vs. non-IR. Protein identif
resistant (IR) and non insulin resistant (non-IR) obese children before FDR aspots. Comparison of protein spot intensities revealed that
8 of them showed significant differences with 5 proteins
increasing after weight loss and the remaining 3 protein
spots decreasing as a consequence of BMI reduction
(Table 4, Figure 3).
Among the observed changes it was remarkable that
weight loss in obese children ameliorated the obesity in-
duced decrease in Apo-A1 by increasing the expression of
two of its isoforms (#2201; #7201), as well as increasing
transthyretin (#5103). No significant differences in HDL
levels (45.83 ± 9.30 vs. 49.42 ± 11.78 mg/dl) were foundication of spots displaying differences (p < 0.05) between insulin
nalysis. For the spot identification, please see Table 3.




MS MS MS MS-MS MS-MS MS-MS
Identification








1704 Downregulated, p < 0.05 126/66 18 64 114/40 10(5) 37 Alpha-1-Antitrypsin
2201 Upregulated, p < 0.01 44/66 3 – 91/41 2(2) 12 Apolipoprotein A1
4801 Downregulated, p < 0.01 90/66 8 25 88/59 4(1) 12 Alpha-1B-glycoprotein
5103 Upregulated, p < 0.05 117/66 8 87 159/57 5(2) 79 Transthyretin
5503 Upregulated, p < 0.05 56/66 6 – 81/59 2(0) 4 Haptoglobin
7201 Upregulated, p < 0.01 106/66 16 66 76/59 3(2) 13 Apolipoprotein A1
7501 Upregulated, p < 0.05 55/66 4 – 86/59 2(2) 4 Haptoglobin
9101 Downregulated, p < 0.05 49/66 3 – 105/55 1(1) 4 Haptoglobin
The second column shows the direction of the change observed after weight loss. Abbreviations: MS Mass spectrometry, MS-MS Tandem mass spectrometry.
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ELISA confirmed the increase in ApoA1 levels after
weight reduction (242.6 ± 75.0 vs. 342.7 ± 83.9, p < 0.01).
Similarly, no influence of weight loss on transthyretin
(19.01 ± 3.95 vs. 19.66 ± 3.56 mg/dl) or RBP4 serum levels
(572.5 ± 150.1 vs. 574.1 ± 127.6 mg/dl) were observed by
kinetic nephelometry and ELISA, respectively.
Weight loss also decreased the expression of one iso-
form of low MW haptoglobin (#9101), whereas two
haptoglobin isoforms with higher MW (#5503; #7501)
were up-regulated after BMI reduction. In contrast, α1-
AT (#1704) and α-1-BAGP (#4801) showed a decrease in
their expression after weight loss. Standard assays were
unable to detect significant changes after weight loss in
serum levels of haptoglobin (177.5 ± 88.1 vs. 152.8 ± 55.6Figure 3 Proteomic profile comparison in Pros-OB: D vs. WL. Protein id
children (Pros-OB) between baseline (D) and after extensive BMI reductionmg/dl), α1-AT (120.2 ± 63.7 vs. 96.3 ± 71.1 mg/dl) or α-
1-BAGP (156.0 ± 53.9 vs. 169.7 ± 43.8 mg/dl).
Discussion
In this study we have shown that obesity can result in
changes in the circulating serum proteome even at
young ages. The intensity of these changes depends
upon the degree of BMI excess in some cases and could
be, at least partially, ameliorated through weight loss.
We have also demonstrated how insulin resistance, the
first step in obesity associated impairment of carbohy-
drate metabolism, enhances these changes in the degree
of expression of specific isoforms of proteins related to
inflammation (haptoglobin) and metabolism (ApoA1),
some of them correlating with serum levels of adipokines,entification of spots displaying intensity differences (p < 0.05) in obese
(WL). For the spot identification, please see Table 4.
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IR. Finally, we have demonstrated that serum proteomic
analysis can complement the clinically used standard
methodology in detecting these initial changes in the con-
centration of isoforms of circulating proteins associated
with obesity related metabolic impairment and can identify
new candidate biomarkers of early metabolic impairment.
One of the proteins significantly found to be affected
in obesity associated IR is Apo-A1. There are two major
classes of Apo-A; Apo-A1 and Apo-A2, with the former
constituting the main component of HDL molecules
[16]. Lipoprotein particles that contain only ApoA-1
(LpA-1 particles) can increase cellular cholesterol efflux
from cultured cells in vitro, whereas LpA-1:A-2 particles
do not [17]. Several studies support the fact that LpA-1
is more effective than LpA1:A-2 in promoting cellular
cholesterol efflux, the first step in reverse cholesterol
transport, leading to inhibition of dietary or genetically
induced atherosclerosis [18]. Moreover, among the HDL
molecules exclusively containing Apo-A1, several sub-
classes have been separated by gel filtration chromatog-
raphy. These have been denoted large, medium and small
LpA-1 and contain different amounts of lipids (much
higher in large Lp-A1). This determines the differences in
their cholesterol-reducing capacity, being lower in large
LpA1 compared with medium and small LpA1 [19]. This
huge variety of circulating HDL and ApoA1 molecules ex-
plains the different isoforms of ApoA1 differentiated by
2DE in our different comparison sets.
Our study affords three important observations regard-
ing Apo-A1 dynamics in young obese children. First, the
observation of the negative correlation found between
BMI-SDS and most Apo-A1 isoforms in the whole cohort
(OB +C) indicates that this is one of the initial derange-
ments in lipid metabolism and that it can already be
present at a very young age. Secondly, when obese children
display IR, Apo-A1 production is more severely impaired.
Finally, it is important to emphasize that the sensitivity of
the standard methodology used in daily practice to deter-
mine HDL and Apo-A1 is insufficient to detect these initial
changes in lipid metabolism demonstrated by 2DE under
the presence of IR. As previously stated, this limited sensi-
tivity can be influenced by the large variety of Apo-A1 and
HDL isoforms [19] that can be selectively modified and/or
change in different directions. In contrast, serum prote-
omic analysis by 2 DE is able to differentiate particular
Apo-A1 isoforms and to detect the subtle and specific
changes induced by obesity associated IR in very young
obese children. Hence, this methodology could comple-
ment commonly used techniques in this subgroup of pa-
tients (insulin resistant obese).
Another apolipoprotein (J), also called clusterin, SGP2,
TRPM-2, or CLI, has shown great variability in response
to different pathological conditions. This is a plasmaprotein with cytoprotective and complement-inhibiting
activities that acts through a specific receptor (megalin)
and is also part of the HDL molecules. HDL molecules
that contain Apo J and Apo A-I carry paraoxonase
(PON1) that protects low-density lipoproteins from oxi-
dative modification [20]. Since its discovery in the 80s, it
has been proposed to influence inflammation and auto-
immunity and to be involved in several pathophysio-
logical processes such as carcinogenesis, kidney injury,
senescence or Alzheimer disease [21].
To our knowledge, no data are available in the litera-
ture regarding serum clusterin dynamics in childhood
obesity. Although the study by Kujiraoka et al. postulates
that serum clusterin levels are unrelated to gender, BMI
or age, it is reported to be increased in coronary heart
disease with a postulated anti-atherogenic effect and its
production enhanced by stress and in T2DM adults [22].
However, the elevation of clusterin in diabetes has been
challenged, as it disappeared after adjusting for the level
of glycemia [20]. Clusterin is known to accumulate in
the artery wall during the development of atherosclerosis
[22] and has been localized in the infarcted heart during
myocardial infarction [23]. Moreover, a protective effect
of exogenous clusterin has been demonstrated on isch-
emically challenged cardiomiocytes in vitro [24].
The differences between groups in clusterin levels ob-
served in this study lost their significance after FDR analysis.
However, the recurrent observation of these differences in
every subset of comparisons established and the negative
correlations with BMI-SDS, HOMA index and visfatin
levels of some of its isoforms suggest an eventual relevance
of this protein in the initial phase of metabolic impairment
in obese children, differing from those observed in adults,
not increasing but decreasing. This could suggest the loss of
its postulated anti-atherogenic and lipid-lowering effects in
direct relationship to of the degree of excess BMI and being
further intensified with the onset of IR. It is possible that
there is a lack of a stress stimulus powerful enough to in-
duce the increase in serum clusterin described in adults as
at these early ages gross metabolic impairment or arterio-
sclerotic changes are absent. The commercially available
ELISA assay was unable to detect the trends to change in
clusterin observed by 2DE, again reinforcing the need for
validation of the changes in clusterin levels observed by
2DE in stages of initial metabolic derangement.
The third group of molecules where multiples changes
were found is the set of haptoglobin isoforms. Obesity
tended to decrease haptoglobin isoforms of higher MW
and increase low MW isoforms, with this last change
found to be significant after FDR analysis. This change was
enhanced when comparing obese IR children with obese
non-IR children, whereas weight loss causes the opposite
effect, inducing an increase in higher MW haptoglobin iso-
forms and a decrease in the low MW ones. This could
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the different isoforms of haptoglobin as a pool, to discrim-
inate these complex changes (as observed in the compari-
son between IR and non-IR).
Apart from the loss of significance of the differences be-
tween groups of several isoforms of haptoglobin after FDR
analysis, two arguments can be raised to support the even-
tual pathophysiological relevance of these observations.
These arguments include the abundance of haptoglobin
isoforms in the serum proteome and the possible influence
of inter-individual genetic variability. In effect, the two al-
leles for haptoglobin (1 and 2) give rise to three major
phenotypes (Hp1-1, Hp2-2 and Hp2-1), each of them with
different capacities to form homo- or hetero-polymers of
haptoglobin [25]. However, the paired comparison per-
formed after weight loss in the same set of children, deter-
mining an increase in the higher MW isoforms and a
decrease in the low MW forms, supports a possible patho-
physiological importance of our observation. Further sup-
port comes from the observed correlations between the
excess of BMI and haptoglobin isoforms, positive for those
with low MW and negative for those with high MW, and
between HOMA index and the low MW isoforms of
haptoglobin.
The increase in the synthesis of low MW isoforms
of haptoglobin in obesity, and further when it associates
IR, could be interpreted as a component of the low-
degree inflammation state accompanying obesity, which
is already present in early ages [6]. Haptoglobin is
an acute phase protein exerting antioxidant activity
through several mechanisms, including activation of
neutrophils, maintenance of reverse cholesterol trans-
port and inhibition of cyclooxygenase and lipooxygen-
ase [26]. This antioxidant function is more pronounced
in individuals with the Hp1-1 phenotype. Interestingly,
this phenotype generates the smallest haptoglobin mole-
cules (dimers), compared with the Hp2-1 (trimers and
tetramers) and Hp2-2 (trimers, tetramers and polymers)
phenotypes, with this last phenotype showing the lowest
antioxidant capacity [25,26]. In this regard, the positive
correlation found between serum IL-6 levels and the
expression of two of the low MW isoforms of haptoglo-
bin (including spot #8102) in our obese cohort suggests
the feasibility of the proposed explanation, especially
taking into account that IL-6 induces haptoglobin syn-
thesis [25,27].
The lack of significance after FDR analysis of the increase
in alpha 1 antitrypsin levels, another acute phase protein,
as a consequence of IR in 2DE analysis as in ELISA does
not allow any conclusion to be made, although its varia-
tions might be expected due to the existence of a proin-
flammatory environment. The increase in alpha-1-acid
glycoprotein detected by ELISA and suggested by 2DE (al-
though not reaching statistical significance after FDR) hasbeen previously reported in obese adults [28] and T2DM
[29], though its biological significance remains uncertain.
Decreased serum levels of some isoforms of two binding
proteins, transthyretin and vD-BP, were observed in obese
children, although they lost their significance after adjust-
ing by FDR. Transtyretin is bound to RBP4 in plasma and
an elevation in RBP4 is thought to contribute to the devel-
opment of IR associated with obesity and T2DM [30] A
decrease in transthyretin could result in increased free
RBP4 levels contributing to IR in obese subjects, with
weight loss improving this impairment. Similarly, low vita-
min D levels have been consistently reported in obese pa-
tients of all ages [31]. Although vitamin D liposolubility
seems to be the main determinant of its low serum levels
in obese subjects, the detected decreases in vitamin D
binding protein isoforms could also be involved. Again
2DE results for trend to change in these two proteins need
further validation, but could confer 2DE a potential role
in early detection of the decrease in specific isoforms of
transtyretin and vD-BP, before changes in total transthyre-
tin, RBP4 or vD-BP are observed.
Regarding the changes observed in protein spot inten-
sity in the three sets of comparison, losing their signifi-
cance after FDR analysis, it should be pointed that,
although correction for multiple comparisons is consid-
ered statistically recommendable to avoid rejecting the
null hypothesis too readily, some author postulate that it
should be avoided. This is explained on the basis that re-
ducing the type I error for null associations increases the
type II error for those associations that are not null; thus
suggesting that a policy of not making adjustments for
multiple comparisons could be preferable because it will
lead to fewer errors of interpretation when the data are
actual observations on nature [32].
Conclusions
Our results suggest that changes in some isoforms of circu-
lating peptides, mainly related to inflammation and lipid
metabolism, accompany the early onset of obesity and IR in
childhood. Furthermore, weight loss can ameliorate these
modifications, at least partially. Some of these changes are
undetectable by methods routinely used in the clinic under
certain conditions, such as IR. Proteomic analysis, in par-
ticular, detection of isoforms of known proteins (ApoA1
and low MW haptoglobin) could be useful to complement
them. In addition, this proteomic approach has allowed for
the identification of several candidate proteins (including
ApoJ/clustering, vitaminD binding protein, transthyretin)
whose dynamics in childhood obesity and IR need further
validation, but could result in novel biomarkers for the risk
of development of obesity related metabolic complications.
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